Immunotherapy is the only breakthrough therapy in cancer treatment in recent years. One main requirement for successful cancer immunotherapy is to generate effective anti-tumor T-cell populations.
ManysmarT Therapeutics aims to deliver highly effective anti-tumor T-cell therapeutics by:
supplying abundant and high purity γ9δ2 T cells at an effector memory cell stage;
combining our ADCC (Antibody-Dependent Cell-mediated Cytotoxicity)-enhancing BiTE (Bispecific T cell Engager) to promote stronger interaction between therapeutic antibodies and the supplied/endogenous T cells and thus, result in a higher ADCC effect than that from using therapeutic antibodies alone;
combining γ9δ2 T cells with our own or commercial BiTEs to synergistically enhance their therapeutic effects;
enabling an easy switch to another therapeutic antibodies/targets to overcome the antigen loss issue commonly observed in advanced cancer;
generating neoantigen-specific T Cell Receptor (TCR)-redirected γ9δ2 T cells for cancer/infectious diseases treatment.